Skip to main content
logo
Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
5.39
+0.39 (7.80%)
At close: Aug 12, 2026, 4:00 PM EDT
5.44
+0.05 (0.93%)
After-hours: Aug 12, 2026, 6:21 PM EDT

Unicycive Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
---0.680.95-
Revenue Growth
----29.02%--
Gross Profit
---0.680.95-
Selling, General & Admin
23.5320.412.18.556.572.9
Research & Development
9.619.1220.0112.912.446.08
Total Operating Expenses
33.1429.5232.1221.45198.98
Operating Income
-33.14-29.52-32.12-20.77-18.05-8.98
Interest Income
1.471.011.260.62--
Interest Expense
-0.04-0.07-0.07-0.08-0.01-0.63
Other Non-Operating Income (Expense)
-3.52.02-5.8-10.3--0.41
Total Non-Operating Income (Expense)
-2.082.96-4.61-9.77-0.01-1.04
Pretax Income
-35.22-26.56-36.73-30.54-18.06-10.02
Net Income
-35.22-26.56-36.73-30.54-18.06-10.02
Net Income Attributable to Preferred Dividends
--1.10.87--
Net Income to Common
-35.22-26.56-37.82-31.41-18.06-10.02
Net Income Growth
------
Shares Outstanding (Basic)
23167221
Shares Outstanding (Diluted)
23167221
Shares Change
104.57%137.17%172.97%62.98%28.96%37.37%
EPS (Basic)
-1.75-1.67-5.65-12.80-12.00-8.60
EPS (Diluted)
-1.75-1.67-5.65-12.80-12.00-8.60
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-27.85-31.34-28.65-18.3-15.65-5.8
Free Cash Flow Growth
------
Free Cash Flow Per Share
-1.23-1.97-4.28-7.46-10.40-4.96
Gross Margin
---100.00%100.00%-
Operating Margin
----3077.63%-1898.21%-
Profit Margin
----4525.04%-1898.84%-
FCF Margin
----2710.37%-1645.95%-
EBITDA
-32.48-28.95-31.69-20.49-17.89-8.96
EBITDA Margin
----3035.56%-1881.28%-
EBIT
-33.14-29.52-32.12-20.77-18.05-8.98
EBIT Margin
----3077.63%-1898.21%-
SEC Filings: 10-K · 10-Q